Press Release Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign Aug 17
Press Release Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRPĀ® Testing for FDA Registration Jul 7